More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. - Wikidata - wikimedia - TriplyDB

More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

http://www.wikidata.org/entity/Q37487110

about

Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy Local therapies for inflammatory eye disease in translation: past, present and future Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.New options for uveitis treatment.Birdshot uveitis: current and emerging treatment options Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments.

P2860

Q34011852-77D30BF9-1832-45E4-980C-FF599026A231 Q34892662-08583C5A-5CC9-40E0-A9F5-CC512F121149 Q36052279-A6CF3A13-1354-43E8-9163-C0E1E70D6625 Q36174993-B37D2A65-F9F1-4849-B30D-84F7F6739D53 Q37256887-17DF5412-692F-4F14-BF00-2988BF9B221C Q37412317-CA2AD950-4E04-4E4F-B133-488171B78582 Q38211433-9E286A16-123D-47F0-8CFE-605B3BF9532D Q38397111-E2FADD79-A30E-424B-B618-46F8A3D73D0B Q45023783-EC53C6A8-B949-490A-A479-0BA6F6BCE60F

P2860

More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

http://www.wikidata.org/entity/Q37487110

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

More questions than answers: a ...... side of a well-designed trial.

@en

More questions than answers: a ...... side of a well-designed trial.

@nl

type

label

More questions than answers: a ...... side of a well-designed trial.

@en

More questions than answers: a ...... side of a well-designed trial.

@nl

prefLabel

More questions than answers: a ...... side of a well-designed trial.

@en

More questions than answers: a ...... side of a well-designed trial.

@nl

P1433

Q37487110-39AF5DC3-4C18-4A2F-A906-7E70B87C7647

P1476

Q37487110-B2C8A2EF-070C-41E7-9E9E-7C2C99A79A64

P2093

Q37487110-19AC9725-226A-4195-9D58-23F545A768FE

Q37487110-654AD0B5-88F2-4CCA-BA13-379FED9AD6AD

Q37487110-700445AF-DB2B-443E-91A1-41BA396C2D1D

Q37487110-954EFD92-A302-4333-9FF4-5D16B1BB6946

P2860

Q37487110-0DB016F9-2F16-4527-AD28-D9D293659A70

Q37487110-0E9327BD-1BB5-40BD-8CD7-9FB6F08BF1C5

Q37487110-107EB99B-018A-4625-81C3-DD9F4373BAFC

Q37487110-1370B55B-AA3C-40EC-A43C-CEBBD9830444

Q37487110-26FEDD58-1757-4A66-BCE1-95920CA76D1F

Q37487110-3C27B52E-FCEA-4C05-8C0E-FCEDDC5F473E

Q37487110-3F310CBB-164A-467E-9B9A-226D7F55F2ED

Q37487110-4DFC7236-28B9-4596-9499-ACC45EB6CFBF

Q37487110-4EEA5081-DD8F-455F-86B3-CCD0F9C1410C

Q37487110-50DAC0D2-5DE3-4859-BC0E-6FEB42379540

P304

Q37487110-29E31DF8-89A5-4D56-A8C2-84BFF44FA734

P31

Q37487110-1abb82fa-09e1-4f12-8c44-3cd26c176594

Q37487110-F2AF6976-C57B-491A-AB03-6C6E285FC01F

P356

Q37487110-F9E846F8-DEAA-4679-A20B-9612AF4E0F0A

P433

Q37487110-688CB2D4-DC2E-4234-AF9D-B33B014F3283

P478

Q37487110-B902B829-D172-46B2-ADCB-CB15840BF3DC

P577

Q37487110-6061270E-8265-477D-8670-A6AA73CED0C2

P698

Q37487110-7C6D3C2B-4EBE-45DB-871A-B5EE891FB50D

P932

Q37487110-80631957-3CA2-4567-9762-8A7FBC1CC542

P356

IAE.0B013E3181CDE727

P1433

P1476

More questions than answers: a ...... side of a well-designed trial.

@en

P2093

Clement J Michet

http://www.w3.org/2001/XMLSchema#string

Jose E Pulido

http://www.w3.org/2001/XMLSchema#string

Jose S Pulido

http://www.w3.org/2001/XMLSchema#string

Richard G Vile

http://www.w3.org/2001/XMLSchema#string

P2860

RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Infliximab stability after reconstitution, dilution, and storage under refrigeration.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Molecular differences in anticytokine therapies.

Immunogenicity of engineered antibodies.

TNFalpha blockade in human diseases: an overview of efficacy and safety.

TNFalpha blockade in human diseases: mechanisms and future directions.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IAE.0B013E3181CDE727

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20061905

http://www.w3.org/2001/XMLSchema#string

P932

3893927

http://www.w3.org/2001/XMLSchema#string